Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas

Yang Rongcun, Flavio Salazar-Onfray, Jehad Charo, Karl Johan Malmberg, Kristina Evrin, Hubert Maes, Koji Kono, Christina Hising, Max Petersson, Olle Larsson, Li Lan, Ettore Appella, Alessandro Sette, Esteban Celis, Rolf Kiessling

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Twenty-two new HLA-A2. 1-binding peptides derived from the protooncogene HER2/neu were identified and analyzed for their capacity to elicit peptide and tumor-specific CTL responses. We used peptide-pulsed autologous DC from the ascites of patients with ovarian carcinomas to induce CTL. Of the 22 tested new HER2/neu-derived epitopes that could bind HLA-A2 with high (IC50 < 50 nM) or intermediate (50 nM< IC50 < 500 nM) affinity, we report the recognition by CTL of at least four novel epitopes, including HER2(9435), HER2(9665), HER2(9689), and HER2(10952), and confirm that of the known HER2 (9369) epitope. These epitopes were able to elicit CTI, that specifically killed peptide-sensitized target cells and, most importantly, a HER2/neu-transfected cell line and the autologous tumor cells. We also confirm that HER2/neu is overexpressed in several melanoma lines, and as a new finding, report that some of these lines are sensitive to CTL induced by the HER2 (9369), HER2(9435), and HER2(9689) epitopes. Finally, CTL clones specific for HER2 (9369), HER2(9435), and HER2(9689) epitopes were isolated from tumor-specific CTL lines, further demonstrating the immunodominance of these epitopes. These findings broaden the potential application of HER2/neu-based immunotherapy.

Original languageEnglish (US)
Pages (from-to)1037-1044
Number of pages8
JournalJournal of Immunology
Volume163
Issue number2
StatePublished - Jul 15 1999

Fingerprint

Epitopes
Melanoma
Carcinoma
Peptides
HLA-A2 Antigen
Tumor Cell Line
Inhibitory Concentration 50
Ascites
Immunotherapy
Neoplasms
Clone Cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Rongcun, Y., Salazar-Onfray, F., Charo, J., Malmberg, K. J., Evrin, K., Maes, H., ... Kiessling, R. (1999). Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. Journal of Immunology, 163(2), 1037-1044.

Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. / Rongcun, Yang; Salazar-Onfray, Flavio; Charo, Jehad; Malmberg, Karl Johan; Evrin, Kristina; Maes, Hubert; Kono, Koji; Hising, Christina; Petersson, Max; Larsson, Olle; Lan, Li; Appella, Ettore; Sette, Alessandro; Celis, Esteban; Kiessling, Rolf.

In: Journal of Immunology, Vol. 163, No. 2, 15.07.1999, p. 1037-1044.

Research output: Contribution to journalArticle

Rongcun, Y, Salazar-Onfray, F, Charo, J, Malmberg, KJ, Evrin, K, Maes, H, Kono, K, Hising, C, Petersson, M, Larsson, O, Lan, L, Appella, E, Sette, A, Celis, E & Kiessling, R 1999, 'Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas', Journal of Immunology, vol. 163, no. 2, pp. 1037-1044.
Rongcun, Yang ; Salazar-Onfray, Flavio ; Charo, Jehad ; Malmberg, Karl Johan ; Evrin, Kristina ; Maes, Hubert ; Kono, Koji ; Hising, Christina ; Petersson, Max ; Larsson, Olle ; Lan, Li ; Appella, Ettore ; Sette, Alessandro ; Celis, Esteban ; Kiessling, Rolf. / Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. In: Journal of Immunology. 1999 ; Vol. 163, No. 2. pp. 1037-1044.
@article{3643446eadda436c9450b32e55e530e1,
title = "Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas",
abstract = "Twenty-two new HLA-A2. 1-binding peptides derived from the protooncogene HER2/neu were identified and analyzed for their capacity to elicit peptide and tumor-specific CTL responses. We used peptide-pulsed autologous DC from the ascites of patients with ovarian carcinomas to induce CTL. Of the 22 tested new HER2/neu-derived epitopes that could bind HLA-A2 with high (IC50 < 50 nM) or intermediate (50 nM< IC50 < 500 nM) affinity, we report the recognition by CTL of at least four novel epitopes, including HER2(9435), HER2(9665), HER2(9689), and HER2(10952), and confirm that of the known HER2 (9369) epitope. These epitopes were able to elicit CTI, that specifically killed peptide-sensitized target cells and, most importantly, a HER2/neu-transfected cell line and the autologous tumor cells. We also confirm that HER2/neu is overexpressed in several melanoma lines, and as a new finding, report that some of these lines are sensitive to CTL induced by the HER2 (9369), HER2(9435), and HER2(9689) epitopes. Finally, CTL clones specific for HER2 (9369), HER2(9435), and HER2(9689) epitopes were isolated from tumor-specific CTL lines, further demonstrating the immunodominance of these epitopes. These findings broaden the potential application of HER2/neu-based immunotherapy.",
author = "Yang Rongcun and Flavio Salazar-Onfray and Jehad Charo and Malmberg, {Karl Johan} and Kristina Evrin and Hubert Maes and Koji Kono and Christina Hising and Max Petersson and Olle Larsson and Li Lan and Ettore Appella and Alessandro Sette and Esteban Celis and Rolf Kiessling",
year = "1999",
month = "7",
day = "15",
language = "English (US)",
volume = "163",
pages = "1037--1044",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas

AU - Rongcun, Yang

AU - Salazar-Onfray, Flavio

AU - Charo, Jehad

AU - Malmberg, Karl Johan

AU - Evrin, Kristina

AU - Maes, Hubert

AU - Kono, Koji

AU - Hising, Christina

AU - Petersson, Max

AU - Larsson, Olle

AU - Lan, Li

AU - Appella, Ettore

AU - Sette, Alessandro

AU - Celis, Esteban

AU - Kiessling, Rolf

PY - 1999/7/15

Y1 - 1999/7/15

N2 - Twenty-two new HLA-A2. 1-binding peptides derived from the protooncogene HER2/neu were identified and analyzed for their capacity to elicit peptide and tumor-specific CTL responses. We used peptide-pulsed autologous DC from the ascites of patients with ovarian carcinomas to induce CTL. Of the 22 tested new HER2/neu-derived epitopes that could bind HLA-A2 with high (IC50 < 50 nM) or intermediate (50 nM< IC50 < 500 nM) affinity, we report the recognition by CTL of at least four novel epitopes, including HER2(9435), HER2(9665), HER2(9689), and HER2(10952), and confirm that of the known HER2 (9369) epitope. These epitopes were able to elicit CTI, that specifically killed peptide-sensitized target cells and, most importantly, a HER2/neu-transfected cell line and the autologous tumor cells. We also confirm that HER2/neu is overexpressed in several melanoma lines, and as a new finding, report that some of these lines are sensitive to CTL induced by the HER2 (9369), HER2(9435), and HER2(9689) epitopes. Finally, CTL clones specific for HER2 (9369), HER2(9435), and HER2(9689) epitopes were isolated from tumor-specific CTL lines, further demonstrating the immunodominance of these epitopes. These findings broaden the potential application of HER2/neu-based immunotherapy.

AB - Twenty-two new HLA-A2. 1-binding peptides derived from the protooncogene HER2/neu were identified and analyzed for their capacity to elicit peptide and tumor-specific CTL responses. We used peptide-pulsed autologous DC from the ascites of patients with ovarian carcinomas to induce CTL. Of the 22 tested new HER2/neu-derived epitopes that could bind HLA-A2 with high (IC50 < 50 nM) or intermediate (50 nM< IC50 < 500 nM) affinity, we report the recognition by CTL of at least four novel epitopes, including HER2(9435), HER2(9665), HER2(9689), and HER2(10952), and confirm that of the known HER2 (9369) epitope. These epitopes were able to elicit CTI, that specifically killed peptide-sensitized target cells and, most importantly, a HER2/neu-transfected cell line and the autologous tumor cells. We also confirm that HER2/neu is overexpressed in several melanoma lines, and as a new finding, report that some of these lines are sensitive to CTL induced by the HER2 (9369), HER2(9435), and HER2(9689) epitopes. Finally, CTL clones specific for HER2 (9369), HER2(9435), and HER2(9689) epitopes were isolated from tumor-specific CTL lines, further demonstrating the immunodominance of these epitopes. These findings broaden the potential application of HER2/neu-based immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0033565301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033565301&partnerID=8YFLogxK

M3 - Article

C2 - 10395702

AN - SCOPUS:0033565301

VL - 163

SP - 1037

EP - 1044

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -